Using a heart monitor to improve treatment outcomes for atrial fibrillation after catheter ablation
Insertable Cardiac Monitor-Guided Early Intervention to Reduce Atrial Fibrillation Burden Following Catheter Ablation (ICM-REDUCE-AF Trial)
This study is looking at how a small heart monitor can help catch early signs of atrial fibrillation returning after treatment, so that people can get the right help sooner, and it’s for patients who have had catheter ablation for this condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-10908601 on NIH RePORTER |
What this research studies
This research investigates how an insertable cardiac monitor can help detect early signs of atrial fibrillation recurrence after catheter ablation. Patients will be monitored continuously to identify subclinical atrial fibrillation, allowing for timely interventions. The study involves randomizing participants into two groups: one receiving early intervention based on monitor data and another following standard care. This approach aims to reduce the burden of atrial fibrillation and improve overall heart health.
Who could benefit from this research
Good fit: Ideal candidates are individuals with drug-refractory paroxysmal or persistent atrial fibrillation who are scheduled for catheter ablation.
Not a fit: Patients who do not have atrial fibrillation or those who are not candidates for catheter ablation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better management of atrial fibrillation, reducing the frequency of episodes and improving patients' quality of life.
How similar studies have performed: Previous research has shown that continuous monitoring can improve outcomes in patients with atrial fibrillation, suggesting this approach may be effective.
Where this research is happening
Rochester, United States
- University of Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Goldenberg, Ilan — University of Rochester
- Study coordinator: Goldenberg, Ilan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.